Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

ANGLE shares jump 30% on AstraZeneca tie-up

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shares jumped 30% following the announcement of a strategic partnership with AstraZeneca PLC (LSE:AZN) that aims to advance...…

ANGLE partners with AstraZeneca in groundbreaking oncology contract

…

AstraZeneca: What The Markets Missing

…

Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca

…

ANGLE inks AstraZeneca deal to develop ground-breaking cancer assay

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug...…

AstraZeneca (AZN) to Report Q1 Earnings: Heres What to Expect

Sales of AstraZenecas (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new…

Verhaltene Kauflaune bei Aktie von AstraZeneca plc (64,2491 €)

Wenig Kursbewegung aktuell bei dem Anteilsschein von AstraZeneca plc . Die Aktie notiert derzeit bei 68,39 US-Dollar. Kaum auffällig ist…

AstraZeneca PLCs (LON:AZN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

AstraZeneca (LON:AZN) has had a great run on the share market with its stock up by a significant 7.5% over…

Was AstraZeneca boss Soriot’s pay rise controversial? Not particularly

It was framed as a pitched battle between two opposing camps in AstraZeneca PLC (LSE:AZN)’s shareholder base. On one side,…

Friday papers: Amazon primed to hit $2tn stock market value

And AstraZeneca chief’s pay rise approved despite shareholder revolt.…

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZenecas (AZN) Enhertu for metastatic HER2-positive solid tumors.…

AstraZenecas (AZN) Fasenra Gets FDA Nod for Asthma in Kids

The FDA approves AstraZenecas (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11…

AstraZeneca Shareholders Vote in Favor of £19 Million CEO Pay

AstraZeneca Plc shareholders backed a pay increase for Pascal Soriot, who is already the highest paid chief executive officer of…

AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot By Reuters

AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot…

Result of AGM

11 April 2024 1730 BST Results of Annual General Meeting held on 11 April 2024 AstraZeneca PLC announced the results of the…

AstraZeneca to boost annual dividend by 7%

…

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM By Reuters

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM…

AstraZeneca increases 2024 dividend by 7%

11 April 2024 AstraZeneca increases 2024 dividend by 7% AstraZeneca announced today that the Board intends to increase the annualised dividend for…

Ihre wichtigsten Termine: Heute im Blick: AstraZeneca, Frosta, Givaudan, VAT, Gerresheimer, Adecco & Emmi

AstraZeneca pay debate exposes disparity in US-UK corporate values

Tomorrow’s shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot’s compensation represents a microcosm of the broader debate around executive...…

AstraZeneca pay debate exposes disparity in US-UK corporate values

Tomorrow’s shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot’s compensation represents a microcosm of the broader debate around executive...…

BARCLAYS stuft ASTRAZENECA auf Overweight

LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 12500…

Krank nach Corona-Impfung - Astrazeneca zu Auskunft verurteilt

BAMBERG (dpa-AFX) - Im Prozess um einen mutmaßlichen Corona-Impfschaden hat eine Frau aus Oberfranken einen Teilerfolg gegen den Hersteller Astrazeneca…

Enhertu approved in US for HER2+ solid tumours

08 April 2024 Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours Based on…

AstraZenecas (AZN) Enhertu Gets FDA Nod for Solid Tumors

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyos Enhertu for HER2-expressing metastatic cancers based on data from three phase II…

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors By Reuters

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors…

Astrazeneca: Wichtiges Medikament erreicht Ziele in Lungenkrebsstudie

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in einer abschließenden klinischen Studie (Phase-III) mit Lungenkrebs-Patienten einen Erfolg erzielt. Das…

Imfinzi improved OS & PFS in limited-stage SCLC

05 April 2024 Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase…

AstraZenecas (AZN) Imfinzi Improves Survival in SCLC Study

AstraZenecas (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase…

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

FDA approves AstraZenecas (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck…

Total Voting Rights

2 April 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

FDA accepts Dato-DXd BLA for breast cancer

2 April 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZenecas (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.…

AstraZenecas (AZN) Rare Blood Disorder Drug Gets FDA Nod

FDA approves AstraZenecas (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult…

AstraZeneca gets FDA approval for PNH drug Voydeya

…

DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Sell

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9500 Pence…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

dpa-AFX ProFeed